RRx-001 Phase 1 Clinical Trial Results Published in Lancet Oncology

[DK37]

Hi Everyone,

A quick update on RRx-001 (for previous info containing preliminary Phase 2 data see: http://coloncancersupport.colonclub.com/viewtopic.php?f=1&t=50662&hilit=rrx+001+trial ).

Although the preliminary Phase 2 data looks encouraging, it is still pending to be seen if it continues to look good in higher patient numbers. I am hoping they will provide a Phase 2 trial clinical update this fall but we'll see........ I am intrigued by this molecule both by the high response rate in the initial small numbers of patients tested as well as the very low side effect profile seen thus far. It appears to resensitize tumors in multiple patients to irinotecan after tumors become resistant.

This week they published in detail their Phase 1 clinical results in the journal "Lancet Oncology". If you are considering this trial, this paper is important for your oncologist to see (along with the preliminary Phase 2 results at the link above) since there is a good chance they have never heard of the molecule. Unfortunately the paper is not free (only the abstract is), costs about $30. http://www.thelancet.com/pdfs/journals/lanonc/PIIS1470-2045(15)00089-3.pdf

It is only being tested at a few sites (UCSD, Stanford and I believe if you have a military connection, at Walter Reed on the east coast) and it is randomized 2:1 to receiving Regorafenib, here is the Clinicaltrials.gov link: https://clinicaltrials.gov/ct2/show/NCT02096354?term=rrx-001&rank=5

-DK

[Stanfordmom]

Thanks for sharing. Very exciting development!

[ieowi]

Thank you DK37, After you mentioned it last time I've been reading a lot about it, seems promising for my father tumor.

Thank you for keeping us updated.

[Nik Colon]

Thanks again DK